Microwave Ablation for Pulmonary Metastases From Colorectal Cancer

CT-guided Percutaneous Microwave Ablation for Pulmonary Metastases From Colorectal Cancer

(MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate CT-guided percutaneous microwave (MW) ablation safety and efficacy in pulmonary metastases from colorectal cancer.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Device: microwave ablation

Detailed Description

From June 2010 to June 2015, 48 unresectable lesions in 32 patients with pulmonary metastases from colorectal cancer were selected for CT-guided microwave ablation. Patients were scheduled for a 1 and 3 month CT follow-up to evaluate lesion diameter.We retrospectively evaluated CT-guided percutaneous microwave (MW) ablation safety and efficacy in pulmonary metastases from colorectal cancer.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Unresectable pulmonary metastases from colorectal cancer.
• diagnosis by CT, and confirmed by percutaneous puncture biopsy.
• Age range 18-70 years old.
• Eastern Cooperative Oncology Group performance status 0-1.
• Life expectancy of more than 3 months.
• Adequate organ function.

Exclusion Criteria:

• Resectable lung metastases.
• Life expectancy less than 3 months
• Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials.
• Coagulopathy with platelet count less than 50000.
• Active infectious disease.
• Age below 18 years.
• Pregnancy of breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treated with microwave ablation; Patients undergoing MWA for pulmonary metastases from colorectal cancer.	Device: microwave ablation; pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Overall Survival (OS)	one year

Secondary Outcome Measures

Outcome Measure	Time Frame
Treatment related adverse events	Eight weeks

Collaborators and Investigators

• Sponsor: The First People's Hospital of Changzhou
• Investigators: Study Director: Jingting Jiang, PD, The First People's Hospital of Changzhou

Publications and helpful links

General Publications

• Cheng G, Shi L, Qiang W, Wu J, Ji M, Lu Q, Li X, Xu B, Jiang J, Wu C. The safety and efficacy of microwave ablation for the treatment of CRC pulmonary metastases. Int J Hyperthermia. 2018 Jun;34(4):486-491. doi: 10.1080/02656736.2017.1366553. Epub 2017 Nov 16.

Study record dates

Study Major Dates

• Study Start: June 1, 2010
• Primary Completion (Actual): June 1, 2015
• Study Completion (Actual): July 1, 2015

Study Registration Dates

• First Submitted: July 15, 2015
• First Submitted That Met QC Criteria: July 16, 2015
• First Posted (Estimate): July 20, 2015

Study Record Updates

• Last Update Posted (Estimate): August 15, 2016
• Last Update Submitted That Met QC Criteria: August 11, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: CRC-MW-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED